ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Lost productivity costs outweigh healthcare costs for Fibromyalgia patients at all severity levels
Friday 17 August 2012
By Arthi Chandran, et al.
[Note: The full text of this article is available free here. ‘Indirect costs’ are the value of lost productivity and unpaid caregiver time. ‘Direct costs’ are costs of health resources used.]
Objectives: To assess:
a) HRU, direct and indirect costs associated with fibromyalgia in routine clinical practice in the United States using a patient-centric approach, and
b) The relationship of fibromyalgia severity level to HRU and costs.
This study recruited a nonprobability convenience sample of 203 subjects aged 18 through 65 years between August 2008 and February 2009 from 20 U.S. community-based physician offices.
Subjects had a prior diagnosis of fibromyalgia by a rheumatologist, neurologist, or pain specialist; received treatment at the enrolling physician's practice for at least 3 months; experienced widespread pain for at least 3 months; and experienced pain in the previous 24 hours.
Subjects completed a 106-item patient questionnaire that included 5 validated health-related quality-of-life instruments and study-specific questions about demographics; clinical history; overall health; treatment satisfaction; and impact of fibromyalgia on cognitive function, daily activities, and employment status.
Subjects also self-reported:
…for the previous 4 weeks.
The 20-item Fibromyalgia Impact Questionnaire total score was used to stratify subjects into fibromyalgia severity groups:
Staff at each site recorded clinical characteristics, health resource use (HRU), and medication use attributable to fibromyalgia on a paper clinical case report form (CRF) based on a 3-month retrospective medical chart review.
Unit costs for 2009 were assigned to the 3-month HRU data reported on the CRF and 4-week subject-reported lost productivity.
Costs were then annualized and reported in the following categories:
Differences across severity levels were evaluated using the Kruskal-Wallis test (continuous measures) and Pearson chi-square or Fisher's exact tests (categorical measures) at the 0.05 alpha level.
Of the 203 subjects, 21 (10.3%) had mild, 49 (24.1%) had moderate, and 133 (65.5%) had severe fibromyalgia.
For subjects with mild, moderate, and severe fibromyalgia, respectively:
…significantly differed across severity levels.
Across severity levels, total medical and nonmedical out-of-pocket costs also differed (P?=?0.025).
Source: Journal of Managed Care Pharmacy, Jul 2012;18(6):415-26. PMID:22839682, by Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. Covance Market Access Services, Inc., Gaithersburg, Maryland, USA. [Email: Caroline.Schaefer@covance.com]
The above originally appeared here.
blog comments powered by Disqus